.png){kind=icon}
.png){kind=icon}
Return
REDOX-RESPONSIVE ORAL DRUG DELIVERY SYSTEMS FOR INFLAMMATORY BOWEL DISEASE: ANALYTICAL CHALLENGES, DESIGN STRATEGIES, AND TRANSLATIONAL OUTLOOK
.png){kind=icon}
OA
AI
B
R
DOI：10.1016/j.ejps.2026.107577.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• The primary cause of IBD disease development was found to be redox imbalance which also served as a method to achieve localized oral drug delivery through its ability to activate at specific locations. • The three polymer chemistries thioketal disulfide and ROS-cleavable polymers were evaluated to determine their effectiveness in activating colon-targeted delivery during times of inflammation. • The mechanistic framework establishes a connection between oxidative pathophysiology together with carrier architecture and trigger selection process to create rational formulation design. • Redox-aware dissolution testing together with degradation-corrected quantification and reaction-transport kinetic modeling establishes new analytical paradigms. • The process of translational advancement needs the following components which include disease-calibrated ROS validation and in vivo mechanistic confirmation and standardized analytics and regulatory-aligned safety assessment.
Keywords:
Inflammatory bowel disease
Redox-responsive drug delivery
Oxidative stress–triggered release
Oral targeted drug delivery
Reactive oxygen species (ROS)
Translational drug delivery systems
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
4.7
Papers:
7.0K
Citations:
1.8W
Organization
Cited Papers